DE58905028D1 - Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel. - Google Patents

Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel.

Info

Publication number
DE58905028D1
DE58905028D1 DE8989114818T DE58905028T DE58905028D1 DE 58905028 D1 DE58905028 D1 DE 58905028D1 DE 8989114818 T DE8989114818 T DE 8989114818T DE 58905028 T DE58905028 T DE 58905028T DE 58905028 D1 DE58905028 D1 DE 58905028D1
Authority
DE
Germany
Prior art keywords
pharmaceutical combination
medicinal product
combination products
antineoplastic
antineoplastic medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE8989114818T
Other languages
English (en)
Inventor
Hans Hermann Prof Grunicke
Dieter Dr Med Herrmann
Johann Dr Hofmann
Elmar Dr Phil Bosies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6361067&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE58905028(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Application granted granted Critical
Publication of DE58905028D1 publication Critical patent/DE58905028D1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
DE8989114818T 1988-08-18 1989-08-10 Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel. Revoked DE58905028D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3827974A DE3827974A1 (de) 1988-08-18 1988-08-18 Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen

Publications (1)

Publication Number Publication Date
DE58905028D1 true DE58905028D1 (de) 1993-09-02

Family

ID=6361067

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3827974A Ceased DE3827974A1 (de) 1988-08-18 1988-08-18 Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
DE8989114818T Revoked DE58905028D1 (de) 1988-08-18 1989-08-10 Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3827974A Ceased DE3827974A1 (de) 1988-08-18 1988-08-18 Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen

Country Status (17)

Country Link
US (2) US5578590A (de)
EP (1) EP0359981B1 (de)
JP (1) JPH02108636A (de)
KR (1) KR900002784A (de)
AT (1) ATE91903T1 (de)
AU (1) AU627207B2 (de)
CA (1) CA1330035C (de)
DD (1) DD283938A5 (de)
DE (2) DE3827974A1 (de)
DK (1) DK401089A (de)
ES (1) ES2058420T3 (de)
HU (1) HUT52396A (de)
IE (1) IE64635B1 (de)
IL (1) IL91343A (de)
NZ (1) NZ230323A (de)
PT (1) PT91470A (de)
ZA (1) ZA896287B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA908852B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
ZA908936B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with quinolyloxazole-2-ones
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5344841A (en) * 1990-11-02 1994-09-06 Sphinx Pharmaceuticals Corporation Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kinase C
US5204370A (en) * 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
ATE155686T1 (de) * 1991-05-14 1997-08-15 Merrell Pharma Inc Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen
AU3320193A (en) * 1991-07-22 1993-02-23 Regents Of The University Of California, The Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5270310A (en) * 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5292737A (en) * 1992-10-23 1994-03-08 Sphinx Pharmaceuticals Corporation N,N'-bis(sulfonamido)-2-amino-4-iminonaphthalen-1-ones and N,N'-bis(amido)-2-amino-4-iminonaphthalen-1-ones
US5844001A (en) * 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
WO1994020106A1 (en) * 1993-03-03 1994-09-15 Kyowa Hakko Kogyo Co., Ltd. Sensitivity enhancer for antineoplastic agent
GB9509572D0 (en) * 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
JPH11509193A (ja) * 1995-06-27 1999-08-17 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン 細胞傷害を増強するための細胞周期動力学の動的遅延方法
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
CA2320117A1 (en) * 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
JP3565003B2 (ja) * 1998-04-02 2004-09-15 日産自動車株式会社 自動車の排水構造
ATE226843T1 (de) * 1998-12-04 2002-11-15 Max Delbrueck Centrum Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
WO2004006842A2 (en) * 2002-07-11 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
CN106434833A (zh) 2004-05-23 2017-02-22 杰勒德·M·豪斯 Theramutein调节剂
ES2246165B1 (es) * 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
WO2007016202A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
CA2622867A1 (en) 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
CA2631182C (en) * 2005-11-23 2019-08-06 Gerard M. Housey Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
CN103816127A (zh) * 2006-11-10 2014-05-28 阿尔法普托斯有限公司 含有三取代甘油化合物的口服剂型
US20100130449A1 (en) * 2006-11-10 2010-05-27 Alphaptose Gmbh Use of Tri-Substituted Glycerol Compounds for the Treatment of Radiation Injuries
CA2873179A1 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Use of bryostatins and neristatins in the treatment of cognitive impairment due to head trauma
CA3226825A1 (en) * 2014-06-19 2015-12-23 Quercis Pharma AG Method for treating cancer with a combination of quercetin and a chemotherapy agent
WO2019169389A1 (en) * 2018-03-02 2019-09-06 Epicentrx, Inc. Methods and compositions for treating cancer and sensitizing tumor cells to kinase inhibitors
US11872241B2 (en) 2018-11-30 2024-01-16 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for reducing major thrombotic events in cancer patients
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0120907A1 (de) * 1982-10-13 1984-10-10 Aston Molecules Limited Pharmazeutische präparate zur anwendung in der therapie von tumoren
WO1989007942A1 (en) * 1988-02-23 1989-09-08 U.S. Bioscience Method for protection from chemotherapeutic side effects
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
ES2058420T3 (es) 1994-11-01
CA1330035C (en) 1994-06-07
IE64635B1 (en) 1995-08-09
DK401089D0 (da) 1989-08-15
DE3827974A1 (de) 1990-02-22
US5770593A (en) 1998-06-23
AU3955089A (en) 1990-02-22
JPH02108636A (ja) 1990-04-20
AU627207B2 (en) 1992-08-20
EP0359981A1 (de) 1990-03-28
KR900002784A (ko) 1990-03-23
DK401089A (da) 1990-02-19
IL91343A (en) 1996-05-14
DD283938A5 (de) 1990-10-31
HUT52396A (en) 1990-07-28
IL91343A0 (en) 1990-03-19
US5578590A (en) 1996-11-26
NZ230323A (en) 1992-05-26
PT91470A (pt) 1990-03-08
EP0359981B1 (de) 1993-07-28
IE892646L (en) 1990-02-18
ZA896287B (en) 1990-05-30
ATE91903T1 (de) 1993-08-15

Similar Documents

Publication Publication Date Title
DE58905028D1 (de) Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel.
DE3883035D1 (de) Saponinkomplexe mit phospholipiden und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
DK393187A (da) Laegemiddel med antitumorvirkning
ATE81588T1 (de) Vasokinetisch wirkende polyungesaettigte saeuren und sie enthaltende pharmazeutische oder kosmetische zubereitungen.
NL194360B (nl) Toedieningsinrichting en combinatie van een toedieningsinrichting en een huis voor houders van de toe te dienen substantie.
NO304982B1 (no) Fosfolipid, fosfatidyletanolamin, farmas°ytisk, nµrings eller kosmetisk blanding omfattende nevnte fosfolipid eller fosfatidyletanolamin
ES2136105T3 (es) Preparacion farmaceutica y/o cosmetica.
ATE223204T1 (de) Liposomenzusammensetzung
ES2058988T3 (es) Preparacion de medicamentos para el tratamiento sistemico de peces ornamentales y utiles.
BR9810267A (pt) Preparados de combinações farmacêuticas, processo para a produção dos mesmos, utilização de preparados de eritropoietina e embalagem unitária farmacêutica
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
ES2091981T3 (es) Procedimiento para la fabricacion de preparaciones de crema estables, hidrofilas o ambifilas, que contienen componentes vesiculares, asi como el uso de las mismas.
NO179436C (no) Fremgangsmåte for fremstilling av farmasöytiske produkter for topisk bruk
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
NO306993B1 (no) Piperidinylmetyloksyzolidin-2-on-derivater, farmasoeytiske preparater som inneholder slike, samt anvendelse av forbindelsene til fremstilling av legemidler
UA32583C2 (uk) Похідні арилтіоалкілтіопіридину
IT1231439B (it) Composizione dietetica e/o farmaceutica per uso orale, contenente un principio attivo scelto tra integratori dietetici e farmaci in veicolo oleoso
ES544042A0 (es) Sistema de envasado,almacenamiento,dosificador,contenedor y en un momento dado,no conocido de antemano,dispensador e in-yector de productos farmaceuticos y-o terapeuticos liquidos de uso humano y veterinario
IT1259140B (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
ATE64305T1 (de) Antikrebstherapie und zytotoxische arzneimittel fuer deren implementation.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: ROCHE DIAGNOSTICS GMBH, 68305 MANNHEIM, DE

8331 Complete revocation